加齢黄斑変性の市場規模、シェア＆動向分析レポート：製品別（エイレア、ルセンティス、ベオーブ）、疾患タイプ別（ウェットAMD、ドライAMD）、流通チャネル別、地域別、セグメント別予測、2022～2030年版

加齢黄斑変性市場の成長と動向

加齢黄斑変性の世界市場規模は、2030年には179億9000万米ドルに達する見込みであることが、Grand View Research, Inc.の最新調査により明らかになりました。2022年から2030年までのCAGRは6.9%で拡大すると予測されています。この成長の背景には、新製品開発のための高い研究開発投資、製品の上市、加齢黄斑変性（AMD）の有病率の上昇、老年人口の増加などがあります。

ウェット型（滲出型）とドライ型（萎縮型）の加齢黄斑変性のうち、ドライ型AMDはより一般的な眼病で、85～90％の症例が網膜に過剰なドルーゼンの発生により視力障害を起こしています。米国国立眼科研究所の統計によると、米国における進行性加齢黄斑変性の有病率は2020年に約300万人とされています。

ドライ型加齢黄斑変性の治療薬として承認された薬剤はまだ存在しません。このため、ドライ型AMDの患者さんのアンメット・メディカル・ニーズに対応する機会が市場関係者にもたらされています。しかし、ウェット型AMDの場合、抗VEGF薬が治療と病状のさらなる悪化の抑制のために使用されています。

しかし、ウェット型AMDの場合、抗VEGF薬による治療が行われますが、通院回数が多く、投与間隔も短いため、治療が完了しないまま患者が治療を中断する傾向があります。主な企業は、より長時間作用する抗VEGF製剤の研究開発に取り組み、需要の増加に対応しています。2020年2月、ノバルティスAGは、同社の製品である黄斑変性症治療薬「ベオーブ」について、欧州委員会から加齢黄斑世代の治療薬として承認を取得しました。本剤は、最初の1年間は12週間の間隔で投与する長時間作用型薬剤です。

また、エフ・ホフマン・ラ・ロシュ・リミテッドの医薬品候補である「バビスモ（ファリシマブ）」は、ローディングドーズ時の注射投与期間が4週間で、2022年1月に加齢黄斑変性の治療薬として米国FDAの承認を取得しました。さらに、2021年10月、ロシュのサスビモがFDAの承認を取得し、2022年に米国に進出する予定です。これはLUCENTIS投与に特化した詰め替え用インプラントで、詰め替え可能期間は6カ月です。これらすべての要因が、予測期間中の市場成長を促進することが期待されます。

EYLEAの特許満了年は、いくつかの特許カテゴリーにより、米国では2023年、欧州では2025年となっています。ルセンティス（F. Hoffmann La Roche Ltd.）は米国で2020年6月に特許を失い、欧州では2022年に特許保護を失う予定です。そのため、バイオシミラー製造企業は、この機会を利用してAMD市場に参入しています。例えば、2021年10月、Formycon AGとBioeq AGは、同社のルセンティスのバイオシミラー版のBLAを米国FDAに受理されました。同申請の審査のためのPDUFA期日は2022年8月の予定です。これら全ての要因が、予測期間中の市場成長を阻害する可能性があります。

加齢黄斑変性市場レポートハイライト

製品別では、高い市場浸透率と特許保護により、2021年にアイリーアが最大の収益シェアを占めました。ビオブは、特許保護と優れた乾燥効果により、予測期間中に最も成長することが予想される

疾患タイプ別では、Eylea、Lucentis、Beovuなどの主要な抗VEGF製品が利用可能であることから、2021年にはwet AMDが最大のシェアを占めました。

北米は2021年に最大の市場シェアを占め、より良い償還施設と治療用の新規加齢黄斑変性治療薬の高い採用率により、予測期間中も優位に立つと予想される

販売チャネル別では、メーカーが自社製品を販売するために専門薬局との提携を進めていることから、専門薬局が予測期間中に最も急速に成長すると予想される

目次

第1章 調査手法と範囲

• 市場セグメンテーション
  • 推定・予測のタイムライン
• 調査手法
• 情報調達
  • 購入したデータベース
  • GVRの内部データベース
  • 二次情報
  • 1次調査
  • 1次調査内容
  • 一次情報一覧
• 情報またはデータ分析
  • データ分析モデル
• 市場の策定と検証
• モデルの詳細
  • コモディティフロー分析
    • アプローチ1：コモディティフローアプローチ
    • アプローチ2：ボトムアップアプローチを使用した国ごとの市場推定
• 世界市場：CAGR計算
• 調査の仮定
• 二次情報一覧
• 略語一覧
• 目的

第2章 エグゼクティブサマリー

• 市場概要

第3章 市場変数、動向、範囲

• 市場系列の見通し
  • 親会社の市場見通し
• 規制の枠組み
• 浸透と成長の見通しのマッピング
• フェーズ別のパイプライン分析
  • 主な今後の製品
• 市場力学
  • 市場促進要因分析
  • 市場抑制分析
• PESTEL分析
• 市場ベースの投与経路の品質分析
  • 硝子体内
  • その他
• 疫学分析
• 満たされていないニーズの分析

第4章 世界の加齢黄斑変性市場- セグメント分析、製品別、2018年から2030年（100万米ドル）、患者シェア（％）

• 世界の加齢黄斑変性市場：製品の変動分析
• アイリーア
• ルセンティス
• ベオヴ
• その他

第5章 世界の加齢黄斑変性市場- セグメント分析、疾患タイプ別、2018年から2030年（100万米ドル）

• 世界の加齢黄斑変性市場：疾患タイプの変動分析
• ドライ AMD
• ウェットAMD

第6章 世界の加齢黄斑変性市場- セグメント分析、流通チャネル別、2018年から2030年（100万米ドル）

• 世界の加齢黄斑変性市場：流通チャネルの変動分析
• 病院薬局
• 専門薬局
• オンライン薬局

第7章 加齢黄斑変性市場：セグメント分析、地域別、2018年から2030年（100万米ドル）

• 加齢黄斑変性市場：地域別の変動分析
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東とアフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第8章 世界の加齢関連黄斑変性症市場：競合分析

• 主要な市場参加者別最近の動向と影響分析
  • 主要な取引と戦略的提携の分析
    • 新製品の発売
    • 合併と買収
    • パートナーシップと契約
• 会社の分類
  • イノベーター
  • 市場のリーダー
  • 新興プレーヤー
  • ヒートマップ分析
• 会社の市況分析
• ベンダー情勢
  • 主要なディストリビューターとチャネルパートナーのリスト
  • 潜在的なエンドユーザーのリスト
  • 主要企業の市場シェア分析、2021年
• Company Market Share, 2021
  • 競合ダッシュボード分析
• プライベートカンパニー
  • 主要新興企業一覧
  • 地域ネットワークマップ
• 企業プロファイル
  • F. Hoffmann-La Roche Ltd.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Novartis AG
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Bayer AG
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Pfizer Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Bausch Health Companies Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Regeneron Pharmaceuticals Inc.
    • 会社概要
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Amgen Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
  • Biogen
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Samsung Bioepis
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Age-Related Macular DegenerationMarket, By Region, 2018 - 2030 (USD Million)
• Table 4 Global Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 5 Global Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 6 GlobalAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 7 North America Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 8 North America Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 9 North America Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 10 U.S. Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 11 U.S. Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 12 U.S.Age-Related Macular DegenerationMarket, By Route of Administration, 2018 - 2030 (USD Million)
• Table 13 Canada Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 14 Canada Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 15 Canada Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 16 Europe Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 17 Europe Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 18 Europe Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 19 Germany Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 20 Germany Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 21 Germany Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 22 U.K. Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 23 U.K. Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 24 U.K.Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 25 France Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 26 France Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 27 France Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 28 Italy Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 29 Italy Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 30 ItalyAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 31 Spain Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 32 Spain Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 33 SpainAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 34 Asia Pacific Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 35 Asia Pacific Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 36 Asia PacificAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 37 Japan Age-Related Macular DegenerationMarket, By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 38 Japan Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 39 JapanAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 40 China Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 41 China Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 42 China Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 43 India Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 44 India Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 45 India Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 46 South Korea Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 47 South Korea Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 48 South Korea Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 49 Australia Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 50 Australia Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 51 Australia Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 52 Latin America Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 53 Latin America Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 54 Latin America Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 55 Brazil Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 56 Brazil Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 57 BrazilAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 58 Mexico Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 59 Mexico Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 60 MexicoAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 61 Argentina Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 62 Argentina Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 63 ArgentinaAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 64 Middle East & Africa Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 65 Middle East & Africa Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 66 Middle East & Africa Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 67 Saudi Arabia Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 68 Saudi Arabia Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 69 Saudi Arabia Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 70 South Africa Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 71 South Africa Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 72 South Africa Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 73 UAE Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
• Table 74 UAE Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
• Table 75 UAEAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Age-Related Macular Degenerationmarket segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modelling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Age-Related Macular Degenerationmarket snapshot
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook, revenue, 2021, (USD Million)
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Age related macular degenerationmarket driver impact
• Fig. 14 Age related macular degenerationmarket restraint impact
• Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
• Fig. 16 Industry Analysis - Porter's
• Fig. 17 Strategy mapping
• Fig. 18 Age-Related Macular Degenerationmarket: Product outlook and key takeaways
• Fig. 19 Age-Related Macular Degenerationmarket: Product movement analysis & market share 2021 & 2030
• Fig. 20 Eyleaage Related Macular Degenerationmarket estimates and forecast, 2018 - 2030 (USD Million) (Patient Share in %)
• Fig. 21 Lucentisage Related Macular Degenerationmarket estimates and forecast, 2018 - 2030 (USD Million)(Patient Share in %)
• Fig. 22 Beovu age Related Macular Degeneration market estimates and forecast, 2018 - 2030 (USD Million)(Patient Share in %)
• Fig. 23 Others age Related Macular Degeneration market estimates and forecast, 2018 - 2030 (USD Million)(Patient Share in %)
• Fig. 24 Age-Related Macular Degenerationmarket: Disease type outlook and key takeaways
• Fig. 25 Age-Related Macular Degenerationmarket: Disease Type movement analysis & market share 2021 & 2030
• Fig. 26 Dry AMD market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Wet AMD market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Age-Related Macular Degenerationmarket: Distribution channel movement analysis & market share 2021 & 2030
• Fig. 29 Hospital Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Specialty Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Online Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Opioids: Regional outlook and key takeaways
• Fig. 33 Regional outlook, 2021 & 2030
• Fig. 34 North America
• Fig. 35 North America market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 U.S.
• Fig. 37 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 Canada
• Fig. 39 Canada market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 40 Europe
• Fig. 41 Europe market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 42 U.K.
• Fig. 43 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 44 Germany
• Fig. 45 Germany market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 46 France
• Fig. 47 France market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 48 Italy
• Fig. 49 Italy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 50 Spain
• Fig. 51 Spain market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 52 Asia Pacific
• Fig. 53 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 54 Japan
• Fig. 55 Japan market estimates and forecast, 2018 - 2030(USD Million)
• Fig. 56 China
• Fig. 57 China market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 58 India
• Fig. 59 India market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 60 South Korea
• Fig. 61 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 62 Australia
• Fig. 63 Australia market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 64 Latin America
• Fig. 65 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 66 Brazil
• Fig. 67 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 68 Mexico
• Fig. 69 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 70 Argentina
• Fig. 71 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 72 Middle East & Africa
• Fig. 73 MEA market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 74 South Africa
• Fig. 75 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 76 Saudi Arabia
• Fig. 77 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 78 UAE
• Fig. 79 UAE market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 80 Market differentiators
• Fig. 81 Key company market share analysis, 2021
• Fig. 82 Company market position analysis
• Fig. 83 Competitive dashboard analysis
• Fig. 84 Regional network map

Age-related Macular Degeneration Market Growth & Trends:

The global age-related macular degeneration market size is expected to reach USD 17.99 billion by 2030, according to a new study by Grand View Research, Inc. It is expected to expand at a CAGR of 6.9% from 2022 to 2030. The growth is due to high R&D investments for new product development, product launches, rising age-related macular degeneration (AMD) prevalence, and the rising geriatric population.

Among wet (exudative) and dry (atrophic) age-related macular degeneration, dry AMD is a more prevalent eye disease with 85-90% of cases causing vision damage due to excessive drusen development in the retina. National Eye Institute statistics suggest that the prevalence of advanced age-related macular degeneration in the U.S. was approximately 3 million in 2020.

There are no approved drugs available yet to treat dry age-related macular degeneration. This creates an opportunity for market players to address the unmet medical needs of dry AMD patients. However, for wet AMD, anti-VEGF drugs are used to treat and control the further deterioration of the condition.

Patients tend to discontinue their treatment without completion owing to frequent clinic visits and administration of drugs at shorter intervals. The key players are engaged in the research & development of longer acting anti-VEGF products to address the increased demand for such products. In February 2020, Novartis AG received approval for its product, Beovu, a macular degeneration drug from the European Commission for the treatment of patients with age-related macular generation. It is a long-acting drug to be administered at an interval of 12 weeks for the first year.

In addition, F. Hoffmann-La Roche Ltd.'s drug candidate, Vabysmo (faricimab), with an injection administration period of 4 weeks during loading dose; received U.S. FDA approval in January 2022 for the treatment of age-related macular degeneration. Furthermore, in October 2021, Roche's Susvimo received FDA approval and is expected to enter the U.S. in 2022. It is a refillable implant specific for LUCENTIS administration, with a refillable duration of six months. All these factors are expected to propel the market growth over the forecast period.

The patent expiry year for EYLEA is 2023 in the U.S. and 2025 in Europe, depending upon several patent categories. Lucentis (F. Hoffmann La Roche Ltd.) lost its patent in June 2020 in the U.S. and will lose patent protection in 2022 in Europe. As a result, biosimilar manufacturing companies are leveraging the opportunity to penetrate the AMD market. For instance, in October 2021, Formycon AG and Bioeq AG received the U.S. FDA acceptance of BLA for the company's biosimilar version of Lucentis. The PDUFA date for the review of the application is scheduled for August 2022. All these factors could hamper the market growth over the forecast period.

Age-related Macular Degeneration Market Report Highlights:

• By product, eylea accounted for the largest revenue share in 2021 owing to the higher market penetration and patent protection. Beovu is anticipated to be the fastest-growing segment over the forecast period due to patent protection and superior drying efficacy

• By disease type, wet AMD held the largest share in 2021 owing to the availability of major anti-VEGF products including Eylea, Lucentis, and Beovu

• North America held the largest market share in 2021 and is expected to dominate over the forecast period due to better reimbursement facilities and the high adoption of novel age-related macular degeneration drugs for the treatment

• Based on distribution channel, specialty pharmacy is expected to be the fastest-growing segment during the forecast period owing to increasing collaboration of manufacturers with specialty pharmacies for distributing their products

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market segmentation
  • 1.1.1 Estimates and forecast timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased database
  • 1.3.2 GVR'S internal database
  • 1.3.3 Secondary sources
  • 1.3.4 Primary research
  • 1.3.5 Details of primary research
  • 1.3.6 List of primary sources
• 1.4 Information or data analysis
  • 1.4.1 Data analysis models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity flow analysis
    • 1.6.1.1 Approach 1: Commodity Flow Approach
    • 1.6.1.2 Approach 2: Country - wise market estimation using bottom - up approach
• 1.7 Global Market: CAGR Calculation
• 1.8 Research Assumptions
• 1.9 List of Secondary Sources
• 1.10 List of Abbreviations
• 1.11 Objectives
  • 1.11.1 Objective 1
  • 1.11.2 Objective 2
  • 1.11.3 Objective 3
  • 1.11.4 Objective 4

Chapter 2 Executive Summary

• 2.1 Market Summary

Chapter 3 Market Variables, Trends & Scope

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent market outlook
• 3.2 Regulatory framework
• 3.3 Penetration and Growth Prospect Mapping
• 3.4 Pipeline Analysis, by Phase
  • 3.4.1 Key upcoming products
• 3.5 Market Dynamics
  • 3.5.1 Market driver analysis
  • 3.5.2 Market restraint analysis
• 3.6 PESTEL Analysis
• 3.7 Quality Analysis of the market based route of administration
  • 3.7.1 Intravitreal
  • 3.7.2 Others
• 3.8 Epidemiology Analysis
• 3.9 Unmet Need Analysis

Chapter 4 Global Age - Related Macular DegenerationMarket - Segment Analysis, By Product, 2018 - 2030 (USD Million), Patient Share (%)

• 4.1 Global Age - Related Macular DegenerationMarket: Product Movement Analysis
• 4.2 Eylea
  • 4.2.1 Eyleaage - related macular degeneration market estimates and forecast, 2018 - 2030 (USD Million), Patient Share (%)
• 4.3 Lucentis
  • 4.3.1 Lucentisage - related macular degeneration market estimates and forecast, 2018 - 2030 (USD Million), Patient Share (%)
• 4.4 Beovu
  • 4.4.1 Beovuage - related macular degeneration market estimates and forecast, 2018 - 2030 (USD Million), Patient Share (%)
• 4.5 Others
  • 4.5.1 Othersage - related macular degeneration market estimates and forecast, 2018 - 2030 (USD Million), Patient Share (%)

Chapter 5 Global Age - Related Macular DegenerationMarket - Segment Analysis, by Disease Type, 2018 - 2030 (USD Million)

• 5.1 Global Age - Related Macular DegenerationMarket: Disease Type Movement Analysis
• 5.2 Dry AMD
  • 5.2.1 Dry AMD market estimates and forecast, 2018 - 2030 (USD Million)
• 5.3 Wet AMD
  • 5.3.1 Wet AMD market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6 Global Age - Related Macular DegenerationMarket - Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

• 6.1 Global Age - Related Macular DegenerationMarket: Distribution Channel Movement Analysis
• 6.2 Hospital Pharmacy
  • 6.2.1 Hospital Pharmacymarket estimates and forecast, 2018 - 2030 (USD Million)
• 6.3 Specialty Pharmacy
  • 6.3.1 Specialty Pharmacymarket estimates and forecast, 2018 - 2030 (USD Million)
• 6.4 Online Pharmacy
  • 6.4.1 Online Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7 Age - Related Macular DegenerationMarket: Segment Analysis, by Region, 2018 - 2030 (USD Million)

• 7.1 Age - Related Macular DegenerationMarket: Regional Movement Analysis
  • 7.1.1 North America
    • 7.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.1.2 U.S.
    • 7.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.1.3 Canada
    • 7.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.1.2 Europe
    • 7.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.2.2 U.K.
    • 7.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.2.3 Germany
    • 7.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.2.4 France
    • 7.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.2.5 Spain
    • 7.1.2.5.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.2.6 Italy
    • 7.1.2.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.1.3 Asia Pacific
    • 7.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.3.2 Japan
    • 7.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.3.3 China
    • 7.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.3.4 India
    • 7.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.3.5 Australia
    • 7.1.3.5.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.3.5 South Korea
    • 7.1.3.5.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.1.4 Latin America
    • 7.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.4.2 Brazil
    • 7.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.4.3 Mexico
    • 7.1.4.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.4.4 Argentina
    • 7.1.4.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.1.5 Middle East & Africa
    • 7.1.5.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.5.2 South Africa
    • 7.1.5.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.5.3 Saudi Arabia
    • 7.1.5.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.5.5 United Arab Emirate
    • 7.1.5.5.1 United Arab Emirates market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Global Age - Related Macular DegenerationMarket: Competitive Analysis

• 8.1 Recent Developments and Impact Analysis, by Key Market Participants
  • 8.1.1 Major deals & strategic alliances analysis
    • 8.1.1.1 New Product Launches
    • 8.1.1.2 Mergers and Acquisitions
    • 8.1.1.3 Partnerships & Agreements
• 8.2 Company Categorization
  • 8.2.1 Innovators
  • 8.2.2 Market Leaders
  • 8.2.3 Emerging Players
  • 8.2.4 Heat Map Analysis
• 8.3 Company Market Position Analysis
• 8.4 Vendor Landscape
  • 8.4.1 List of Key Distributors and Channel Partners
  • 8.4.2 List of Potential End Users
  • 8.4.3 Key Company Market Share Analysis, 2021
• 8.5 Company Market Share, 2021
  • 8.5.1 Competitive Dashboard Analysis
• 8.6 Private Companies
  • 8.6.1 List of Key Emerging Companies
  • 8.6.2 Regional Network Map
• 8.7 Company Profiles
  • 8.7.1 F. Hoffmann - La Roche Ltd.
    • 8.7.1.1 Company overview
    • 8.7.1.2 Financial performance
    • 8.7.1.3 Product benchmarking
    • 8.7.1.4 Strategic initiatives
  • 8.7.2 Novartis AG
    • 8.7.2.1 Company overview
    • 8.7.2.2 Financial performance
    • 8.7.2.3 Product benchmarking
    • 8.7.2.4 Strategic initiatives
  • 8.7.3 Bayer AG
    • 8.7.3.1 Company overview
    • 8.7.3.2 Financial performance
    • 8.7.3.3 Product benchmarking
    • 8.7.3.4 Strategic initiatives
  • 8.7.4 Pfizer Inc.
    • 8.7.4.1 Company overview
    • 8.7.4.2 Financial performance
    • 8.7.4.3 Product benchmarking
    • 8.7.4.4 Strategic initiatives
  • 8.7.5 Bausch Health Companies Inc.
    • 8.7.5.1 Company overview
    • 8.7.5.2 Financial performance
    • 8.7.5.3 Product benchmarking
    • 8.7.5.4 Strategic initiatives
  • 8.7.6 Regeneron Pharmaceuticals Inc.
    • 8.7.6.1 Company overview
    • 8.7.6.2 Product benchmarking
    • 8.7.6.3 Strategic initiatives
  • 8.7.7 Amgen Inc.
    • 8.7.7.1 Company overview
    • 8.7.7.2 Financial performance
    • 8.7.7.3 Product benchmarking
  • 8.7.8 Biogen
    • 8.7.8.1 Company overview
    • 8.7.8.2 Financial performance
    • 8.7.8.3 Product benchmarking
    • 8.7.8.4 Strategic initiatives
  • 8.7.9 Samsung Bioepis
    • 8.7.9.1 Company overview
    • 8.7.9.2 Financial performance
    • 8.7.9.3 Product benchmarking
    • 8.7.9.4 Strategic initiatives